Recordati stock holds up after a stronger first half

Recordati (ISIN IT0003828271) is supported by first-half 2026 reporting that showed revenue of EUR 1.19 billion, adjusted EBITDA of EUR 438.7 million, and adjusted net profit of EUR 257.3 million. The Milan-listed group said the figures were published in its 2026 interim update and give investors a dated read on profitability and cash generation.

Revenue and profit

Revenue reached EUR 1.19 billion in the first half of 2026, while adjusted EBITDA came in at EUR 438.7 million and adjusted net profit at EUR 257.3 million. Those are the three core metrics that frame the stock: top line, operating profit, and bottom-line earnings all sit on the same reporting date.

The comparison point matters too. Recordati said first-half 2026 results were ahead of the prior-year base on several operating lines, giving the share a more defensible valuation anchor than a purely sentiment-led move.

Margin stays central

Adjusted EBITDA of EUR 438.7 million against revenue of EUR 1.19 billion implies a margin above 36% for the period, which underlines why the market often treats Recordati as a defensively profitable pharmaceuticals name. For a stock in the healthcare sector, that mix of recurring demand and high margin is the key investment variable.

The company also pointed to a solid earnings profile in the half-year period, with adjusted net profit of EUR 257.3 million. That gives a clear second layer of evidence beyond revenue and makes the reporting cycle relevant for assessing the share price.

Listing context

Recordati stock trades in Milan, where investors usually judge it against European healthcare peers and earnings momentum rather than short-term sentiment. The company name and ticker context are most useful when paired with the half-year numbers, because the reporting update rather than a one-off headline drives the valuation debate.

Recordati medicines

Recordati’s product base is centered on specialty and rare-disease medicines, a portfolio that supports repeat demand and helps explain why half-year margins remain the focus. The business is less about volume spikes than about steady contribution from branded therapies and niche treatments.

Milan close

As a market reference, Recordati stock should be read alongside its Milan listing and the company’s reported first-half 2026 figures. The latest evidence in this article is the period-specific half-year update, which puts EUR 1.19 billion of revenue, EUR 438.7 million of adjusted EBITDA, and EUR 257.3 million of adjusted net profit at the center of the story.